Atika Capital Management LLC Immunovant, Inc. Transaction History

Atika Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$30.27 - $43.79 $1.21 Million - $1.75 Million	40,000 Added 33.33%	160,000 $5.17 Million
Q4 2023 Feb 13, 2024	SELL	$31.31 - $44.19 $2.79 Million - $3.93 Million	-89,000 Reduced 42.58%	120,000 $5.06 Million
Q3 2023 Nov 13, 2023	BUY	$18.55 - $39.96 $3.88 Million - $8.35 Million	209,000 New	209,000 $8.02 Million
Q1 2021 May 14, 2021	SELL	$13.08 - $49.6 $1.56 Million - $5.91 Million	-119,198 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$36.36 - $52.71 $79,919 - $115,856	2,198 Added 1.88%	119,198 $5.51 Million
Q3 2020 Nov 13, 2020	BUY	$22.61 - $38.9 $2.65 Million - $4.55 Million	117,000 New	117,000 $4.12 Million

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Atika Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Atika Capital Management LLC with notifications on news.